Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sogue Coulibaly"'
Autor:
Paolo Rossato, Enrica Federti, Alessandro Matte, Helmut Glantschnig, Fabio Canneva, Maria Schuster, Sogue Coulibaly, Gerald Schrenk, Dirk Voelkel, Michael Dockal, Barbara Plaimauer, Immacolata Andolfo, Achille Iolascon, Hanspeter Rottensteiner, Herbert Gritsch, Friedrich Scheiflinger, Werner Hoellriegl, Lucia De Franceschi
Publikováno v:
Haematologica, Vol 107, Iss 11 (2022)
Sickle cell disease (SCD) is an inherited red blood cell disorder that occurs worldwide. Acute vaso-occlusive crisis is the main cause of hospitalization in patients with SCD. There is growing evidence that inflammatory vasculopathy plays a key role
Externí odkaz:
https://doaj.org/article/8c70e0b3cd1f416b96b51f9736f32503
Autor:
Johannes Lengler, Sogue Coulibaly, Bernadette Gruber, Reinhard Ilk, Josef Mayrhofer, Friedrich Scheiflinger, Werner Hoellriegl, Falko G. Falkner, Hanspeter Rottensteiner
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 581-588 (2020)
Gene therapy product release requires reliable and consistent demonstration of biopotency. In hemophilia B vectors, this is usually determined in vivo by measuring the plasma levels of the expressed human factor IX (FIX) transgene product in FIX knoc
Externí odkaz:
https://doaj.org/article/385fb00f577f4457ac3b71706cbf6f70
Autor:
Annett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, Daniel Portsmouth, Thomas R Kreil, Brian A Crowe, Michael G Schwendinger, Andreas Pilz, P Noel Barrett, Falko G Falkner, Birgit Schäfer
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88340 (2014)
BACKGROUND: The availability of a universal influenza vaccine able to induce broad cross-reactive immune responses against diverse influenza viruses would provide an alternative to currently available strain-specific vaccines. We evaluated the abilit
Externí odkaz:
https://doaj.org/article/fe46820da6be43fb9b924fc38d53fccf
Autor:
Birgit Schäfer, Georg W Holzer, Alexandra Joachimsthaler, Sogue Coulibaly, Michael Schwendinger, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24505 (2011)
BACKGROUND: Currently existing yellow fever (YF) vaccines are based on the live attenuated yellow fever virus 17D strain (YFV-17D). Although, a good safety profile was historically attributed to the 17D vaccine, serious adverse events have been repor
Externí odkaz:
https://doaj.org/article/8754ddabd43445ef9a1b4f87c1302bc2
Autor:
Annett Hessel, Michael Schwendinger, Georg W Holzer, Klaus K Orlinger, Sogue Coulibaly, Helga Savidis-Dacho, Marie-Luise Zips, Brian A Crowe, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett, Falko G Falkner
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e16247 (2011)
BACKGROUND: New highly pathogenic H5N1 influenza viruses are continuing to evolve with a potential threat for an influenza pandemic. So far, the H5N1 influenza viruses have not widely circulated in humans and therefore constitute a high risk for the
Externí odkaz:
https://doaj.org/article/aa02955da4be48a892c3e65736b41f70
Autor:
Annett Hessel, Michael Schwendinger, Daniela Fritz, Sogue Coulibaly, Georg W Holzer, Nicolas Sabarth, Otfried Kistner, Walter Wodal, Astrid Kerschbaum, Helga Savidis-Dacho, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12217 (2010)
BACKGROUND: The development of novel influenza vaccines inducing a broad immune response is an important objective. The aim of this study was to evaluate live vaccines which induce both strong humoral and cell-mediated immune responses against the no
Externí odkaz:
https://doaj.org/article/2b24e378b3064e2aa532a5ed5adbfba7
Autor:
Sogue Coulibaly, Friedrich Scheiflinger, Josef Mayrhofer, Hanspeter Rottensteiner, Reinhard Ilk, Werner Hoellriegl, Bernadette Gruber, Falko G. Falkner, Johannes Lengler
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 581-588 (2020)
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss, Pp 581-588 (2020)
Gene therapy product release requires reliable and consistent demonstration of biopotency. In hemophilia B vectors, this is usually determined in vivo by measuring the plasma levels of the expressed human factor IX (FIX) transgene product in FIX knoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb849e8599c86f72ce720421abe2e77
http://europepmc.org/articles/PMC7139127
http://europepmc.org/articles/PMC7139127
Autor:
Maurus de la Rosa, Stefan Romeder-Finger, Sogue Coulibaly, Sebastian Dorn, Frank M. Horling, Alfred Weber, Herwig Koppensteiner, Bettina Hartlieb, Birgit M. Reipert, Anita Kruzik, Friedrich Scheiflinger, Werner Hoellriegl, Damir Fetahagic
Publikováno v:
Human Gene Therapy Methods. 30:35-43
Patients with preexisting anti-adeno-associated virus serotype 8 (AAV8) neutralizing antibodies (NAbs) are currently excluded from AAV8 gene therapy trials. Therefore, the assessment of biologically relevant AAV8-NAb titers is critical for product de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca0c15561b1e06e1264ce44fc11bb59
https://doi.org/10.1089/hgtb.2018.263
https://doi.org/10.1089/hgtb.2018.263
Autor:
Marinee Chuah, Thierry VandenDriessche, Maria Schuster, Friedrich Scheiflinger, Werner Höllriegl, Sogue Coulibaly, Kefeng Sun, Hanspeter Rottensteiner, Helen Wang, Markus Weiller
Introduction: Adeno-associated virus (AAV)-based factor IX (FIX) gene therapy has the potential to provide clinical benefit in patients with hemophilia B. TAK-748 is a novel next-generation AAV vector for FIX gene therapy. The vector design includes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eaf7a9c989384cd9b436ec5d46b00c2
https://doi.org/10.1182/blood-2019-124734
https://doi.org/10.1182/blood-2019-124734
Autor:
Anita, Kruzik, Herwig, Koppensteiner, Damir, Fetahagic, Bettina, Hartlieb, Sebastian, Dorn, Stefan, Romeder-Finger, Sogue, Coulibaly, Alfred, Weber, Werner, Hoellriegl, Frank M, Horling, Friedrich, Scheiflinger, Birgit M, Reipert, Maurus, de la Rosa
Publikováno v:
Human gene therapy methods. 30(2)
Patients with preexisting anti-adeno-associated virus serotype 8 (AAV8) neutralizing antibodies (NAbs) are currently excluded from AAV8 gene therapy trials. Therefore, the assessment of biologically relevant AAV8-NAb titers is critical for product de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::466e94e2941c572f3c38aab786442b38
https://pubmed.ncbi.nlm.nih.gov/30734588
https://pubmed.ncbi.nlm.nih.gov/30734588